Separate terms with OR to return results that match either term.
 
Clear All

628 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) (Ascending) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J8650 Nabilone Cesamet 1 mg Ancillary Therapy Antiemetic Cannabinoid Yes 1985 Jan. 1, 2007 In Use
J8655 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 Jan. 1, 2016 In Use
Q9978 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 July 1, 2015 Dec. 31, 2015 No Longer Used
C9448 Netupitant/palonostron Akynzeo 300mg/0.5 mg Ancillary Therapy Antiemetic 5HT3 Receptor Anatagonist/Substance P/Neurokinin 1 Yes 2014 April 1, 2015 June 30, 2015 No Longer Used
Q0179 Ondansetron Zofran, Zofran ODT, Zuplenz 8 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 April 1, 1998 Dec. 31, 2011 No Longer Used
Q0162 Ondansetron with active chemotherapy treatment adminstration Zofran, Zofran ODT, Zuplenz 1 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
S0181 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2002 Dec. 31, 2011 No Longer Used
S0119 Ondansetron Zofran, Zofran ODT, Zuplenz 4 mg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Yes 1991 Jan. 1, 2012 In Use
NA oxymetholone Anadrol-50 50 mg Ancillary Therapy Anabolic Steroid Androgen Yes 1972 In Use
J8670 Rolapitant Varubi 1 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2015 Jan. 1, 2017 In Use

Found 628 results in 1 millisecondExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.